Nov 21, 2019 : AbbVie, a research-based global biopharmaceutical company announced that between Dec 7- 10 in American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando more than 40 abstracts, including 18 oral presentations will be presented that include presentations on Ibrutinib (IMBRUVICA®) plus venetoclax (VENCLEXTA®/VENCLYXTO®) , which helps improving the lives of people living with various difficult-to-treat blood cancers.
IMBRUVICA (ibrutinib) blocks a protein called Bruton’s tyrosine kinase (BTK). It is an oral, once-daily medicine that works in a different way than chemotherapy.
VENCLEXTA®/VENCLYXTO® (venetoclax) selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. VENCLEXTA/VENCLYXTO targets the BCL-2 protein and helps to restore the apoptosis process. https://news.abbvie.com/news/press-releases/abbvie-to-present-latest-clinical-research-in-treatment-leukemias-lymphomas-and-other-blood-cancers-at-2019-ash-annual-meeting.htm
